MX2024008598A - Usos de un modulador de somatostatina para el tratamiento del sindrome carcinoide. - Google Patents
Usos de un modulador de somatostatina para el tratamiento del sindrome carcinoide.Info
- Publication number
- MX2024008598A MX2024008598A MX2024008598A MX2024008598A MX2024008598A MX 2024008598 A MX2024008598 A MX 2024008598A MX 2024008598 A MX2024008598 A MX 2024008598A MX 2024008598 A MX2024008598 A MX 2024008598A MX 2024008598 A MX2024008598 A MX 2024008598A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- carcinoid syndrome
- somatostatin modulator
- somatostatin
- modulator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298551P | 2022-01-11 | 2022-01-11 | |
| PCT/US2023/010493 WO2023137018A1 (en) | 2022-01-11 | 2023-01-10 | Uses of a somatostatin modulator for the treatment of carcinoid syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008598A true MX2024008598A (es) | 2024-07-23 |
Family
ID=87279605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008598A MX2024008598A (es) | 2022-01-11 | 2023-01-10 | Usos de un modulador de somatostatina para el tratamiento del sindrome carcinoide. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250228842A1 (enExample) |
| EP (1) | EP4463159A4 (enExample) |
| JP (1) | JP2025501922A (enExample) |
| KR (1) | KR20240132451A (enExample) |
| CN (1) | CN118510511A (enExample) |
| AU (1) | AU2023207068A1 (enExample) |
| CA (1) | CA3242165A1 (enExample) |
| IL (1) | IL314054A (enExample) |
| MX (1) | MX2024008598A (enExample) |
| TW (1) | TW202339747A (enExample) |
| WO (1) | WO2023137018A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4482491A4 (en) * | 2022-02-25 | 2026-02-25 | Amryt Endo Inc | ORAL OCTREOTIDE FOR THE TREATMENT OF A DISEASE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
| AU2017296392B2 (en) * | 2016-07-14 | 2020-09-24 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| MA51625B1 (fr) * | 2018-01-17 | 2022-07-29 | Crinetics Pharmaceuticals Inc | Procédé de production de modulateurs de somatostatine |
| US12617767B2 (en) * | 2019-07-17 | 2026-05-05 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of somatostatin modulators |
| WO2022055880A1 (en) * | 2020-09-09 | 2022-03-17 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
-
2023
- 2023-01-10 IL IL314054A patent/IL314054A/en unknown
- 2023-01-10 CA CA3242165A patent/CA3242165A1/en active Pending
- 2023-01-10 AU AU2023207068A patent/AU2023207068A1/en active Pending
- 2023-01-10 JP JP2024538962A patent/JP2025501922A/ja active Pending
- 2023-01-10 CN CN202380016138.8A patent/CN118510511A/zh active Pending
- 2023-01-10 WO PCT/US2023/010493 patent/WO2023137018A1/en not_active Ceased
- 2023-01-10 MX MX2024008598A patent/MX2024008598A/es unknown
- 2023-01-10 KR KR1020247021853A patent/KR20240132451A/ko active Pending
- 2023-01-10 EP EP23740602.0A patent/EP4463159A4/en active Pending
- 2023-01-10 US US18/727,827 patent/US20250228842A1/en active Pending
- 2023-01-10 TW TW112101029A patent/TW202339747A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3242165A1 (en) | 2023-07-20 |
| US20250228842A1 (en) | 2025-07-17 |
| JP2025501922A (ja) | 2025-01-24 |
| WO2023137018A1 (en) | 2023-07-20 |
| AU2023207068A1 (en) | 2024-07-11 |
| EP4463159A1 (en) | 2024-11-20 |
| TW202339747A (zh) | 2023-10-16 |
| EP4463159A4 (en) | 2026-01-14 |
| KR20240132451A (ko) | 2024-09-03 |
| CN118510511A (zh) | 2024-08-16 |
| IL314054A (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| AR108711A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| MX2021006552A (es) | Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita. | |
| CR20220074A (es) | Regímenes de dosificación para inhibidores orales del factor d del complemento | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| ES2171109B2 (es) | Derivados de 4-fenil-piridina. | |
| AR117920A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO2022005926A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| ECSP22085221A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| MX2021013980A (es) | Compuesto para el tratamiento de gota o hiperuricemia. | |
| EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
| MX2019014024A (es) | Tratamiento de los trastornos depresivos. | |
| CL2023000627A1 (es) | Formulaciones de un modulador de somatostatina | |
| AR118729A1 (es) | Inhibidor selectivo de la jak1 quinasa | |
| CL2019000377A1 (es) | Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren | |
| PY2228756A (es) | Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5) | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| MX2022003945A (es) | Metodo para tratar vih con cabotegravir y rilpivirina. | |
| MX2025009866A (es) | Metodos de uso de inhibidores del factor b | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
| CA3242165A1 (en) | Uses of a somatostatin modulator for the treatment of carcinoid syndrome |